- Home
- MRNA vs HTHT Comparison
MRNA vs HTHT Comparison
Compare MRNA & HTHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRNA | HTHT |
|---|---|---|
| Founded | 2010 | 2005 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 11.4B |
| IPO Year | 2018 | 2010 |
Fundamental Metrics
Financial Performance| Metric | MRNA | HTHT |
|---|---|---|
| Price | $27.74 | $47.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 2 |
| Target Price | $33.91 | ★ $47.00 |
| AVG Volume (30 Days) | ★ 9.9M | 2.0M |
| Earning Date | 11-06-2025 | 11-17-2025 |
| Dividend Yield | N/A | ★ 4.05% |
| EPS Growth | N/A | ★ 7.24 |
| EPS | N/A | ★ 1.76 |
| Revenue | $2,232,000,000.00 | ★ $3,484,239,807.00 |
| Revenue This Year | N/A | $7.07 |
| Revenue Next Year | $0.77 | $6.65 |
| P/E Ratio | ★ N/A | $27.26 |
| Revenue Growth | N/A | ★ 5.77 |
| 52 Week Low | $22.28 | $30.13 |
| 52 Week High | $48.92 | $47.97 |
Technical Indicators
Market Signals| Indicator | MRNA | HTHT |
|---|---|---|
| Relative Strength Index (RSI) | 60.85 | 74.63 |
| Support Level | $23.92 | $45.44 |
| Resistance Level | $26.00 | $47.76 |
| Average True Range (ATR) | 1.29 | 1.44 |
| MACD | 0.32 | 0.06 |
| Stochastic Oscillator | 99.82 | 98.80 |
Price Performance
Historical ComparisonAbout MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About HTHT H World Group Limited
H World Group Ltd is a multi-brand hotel group in China with international operations. It operates in the leased, managed, and franchised models. The company has two operating segments: legacy Huazhu and legacy DH. Its brand and product offering includes Economy hotel brands: HanTing Hotel, Ni Hao Hotel, Hi Inn, Elan Hotel, Zleep Hotels, and Ibis Hotel, Midscale hotel brands: JI Hotel, Orange Hotel, Starway Hotel and Ibis Styles Hotel, Upper midscale hotel brands: Crystal Orange Hotel, IntercityHotel, Manxin Hotel, Mercure Hotel, Madison Hotel, Novotel Hotel, CitiGO Hotel and MAXX by Steigenberger, Upscale hotel brands: Joya Hotel, Blossom House, Steigenberger Hotels & Resorts, Jaz in the City, and Grand Mercure; and Luxury hotel brand: Steigenberger Icon and Song Hotels.